Friday, Dec 01, 2023
×
Outlook.com
×

Usfda Approval

Zydus Gets Nod For Phase II Clinical Study In Patients With CAPS In Australia

Zydus Lifesciences Gets USFDA Nod For Generic Rheumatoid Arthritis Treatment Drug

As per the USFDA, it may designate a drug as a CGT after determining that there is inadequate generic competition for that drug

03 August 2023

Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world

Alembic Pharmaceuticals Gets USFDA Nod For Hypertension Drug

Alembic has a cumulative total of 183 ANDA (abbreviated new drug application) approvals from the US Food & Drug Administration

08 March 2023

Glenmark Gets USFDA Nod For Generic Diabetes Drug

Glenmark said it has received approval from the US health regulator to market a generic medication to treat diabetes in the American market

17 February 2023

Zydus

Zydus Lifesciences Gets Final USFDA Approval To Mfg, Market Generic Version Of Varenicline Tablets

The approval by the US Food and Drug Administration (USFDA) is for Varenicline tablets of strengths 0.5 mg and 1 mg, Zydus said in a regulatory filing.

13 June 2023

USFDA Rejects Biocon, Viatris Application For Insulin Aspart

Zydus Gets USFDA Nod For Generic Products

The company has received approval from the US Food and Drug Administration (USFDA) to market Gabapentin tablets which are indicated for the management of postherpetic neuralgia (PHN)

20 February 2023

Lupin gets USFA approval

Lupin Bags USFDA Nod To Market Generic Product In US Market

The approval for Glycopyrrolate clears the path for more internally manufactured injectable products

09 February 2023

Zydus Lifesciences Gets Final Approval From USFDA For Azithromycin Tablets

Azithromycin is indicated to treat certain bacterial infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), infections of the ears, lungs, sinuses, skin, throat, and reproductive organs

10 April 2023

Advertisement

Zydus Lifesciences Arm Gets USFDA Nod To Market Generic Levomilnacipran ER Capsules

Zydus Lifesciences Arm Gets USFDA Nod To Market Generic Levomilnacipran ER Capsules

Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in adults, Zydus Lifesciences said

16 January 2023

Advertisement
10 December 2022
Zydus Gets USFDA Nod For Two Generic Drugs

Zydus Gets USFDA Nod For Two Generic Drugs

The company has also received final approval from the US Food and Drug Administration (USFDA) to market Pregabalin capsules in multiple strengths, the...


17 October 2022
Zydus Lifesciences Gets USFDA Nod For 2 Generic Drugs

Zydus Lifesciences Gets USFDA Nod For 2 Generic Drugs

As per IQVIA MAT August 2022 data, Valbenazine capsules had annual sales of USD 781 million in the US


04 October 2022
Lupin Gets USFDA Nod For Generic HIV Drug 

Lupin Gets USFDA Nod For Generic HIV Drug 

The Mumbai-based company said it is the exclusive first filer for 800 mg tablets and is eligible for 180-day exclusivity


24 May 2022
FDA Lifts Hold On Covaxin's Clinical Trials In US

FDA Lifts Hold On Covaxin's Clinical Trials In US

FDA had earlier implemented a temporary pause on Covaxin trials, following the WHO's observations on Covaxin manufacturing plants in India.


18 April 2022
Lupin Gets USFDA Nod To Market Generic Drug

Lupin Gets USFDA Nod To Market Generic Drug

The company has received tentative approval from the United States Food and Drug Administration for its abbreviated new drug application for Tenofovir...


Advertisement

14 April 2022
Lupin Receives USFDA Approval For Anti-Depressant Drug

Lupin Receives USFDA Approval For Anti-Depressant Drug

The approval granted by the US Food and Drug Administration is for the abbreviated new drug application Desvenlafaxine extended-release tablets of strength 25...


Advertisement
Advertisement
Advertisement
Advertisement
Advertisement